Recordando a Dan Perez, cofundador de la FSHD Society e impulsor de la investigación y la defensa de la FSHD.
Español de México
On October 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, Inc., marking another important advancement for the FSHD community. With this acquisition, Novartis, […]
Author: Dr. Raymond A. Huml, Vice President, Rare Disease Strategy, Sciensus The Rare Trials Summit in Boston, held on September 9 & 10, 2025, was the inaugural event driven by […]
The company switches up its strategy and plans to develop muscle stem cells that evade the immune system by June Kinoshita, FSHD Society Hot off the press is this news […]
The FSH Society has a long history of partnering with biotech and pharmaceutical companies to facilitate recruitment of patients and families for focus groups, provide patient input to clinical outcome […]
Highlights include: Report from the 2013 International Research Consortium meeting in Cambridge, Massachusetts. Advances in basic research, clinical trials and future drug targets. Introducing our new Celebrity Honorary Board. Stars […]
English English 
العربية
Español de México
Français du Canada
简体中文
